The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Timeframe: Screening
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Timeframe: Day 1
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Timeframe: Day 7
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Timeframe: Day 14
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Timeframe: Day 21
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Timeframe: Day 28
To evaluate the PK of oral doses of MYMD1 capsules
Timeframe: Cohorts 1, 2, 3, 4: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24 hrs; Day 7, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24; Day 14, pre-dose, 0.5 hrs; Day 21, pre-dose, 0.5 hrs; Day 28, pre-dose, 0.5 hrs]
To evaluate the PK of oral doses of MYMD1 capsules
Timeframe: Cohorts 1, 2, 3, 4: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24 hrs; Day 7, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24; Day 14, pre-dose, 0.5 hrs; Day 21, pre-dose, 0.5 hrs; Day 28, pre-dose, 0.5 hrs]
To evaluate the PK of oral doses of MYMD1 capsules
Timeframe: Cohorts 1, 2, 3, 4: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24 hrs; Day 7, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24; Day 14, pre-dose, 0.5 hrs; Day 21, pre-dose, 0.5 hrs; Day 28, pre-dose, 0.5 hrs]
To evaluate the PK of oral doses of MYMD1 capsules
Timeframe: Cohorts 1, 2, 3, 4: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24 hrs; Day 7, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24; Day 14, pre-dose, 0.5 hrs; Day 21, pre-dose, 0.5 hrs; Day 28, pre-dose, 0.5 hrs]
To evaluate the PK of oral doses of MYMD1 capsules
Timeframe: Cohorts 1, 2, 3, 4: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24 hrs; Day 7, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24; Day 14, pre-dose, 0.5 hrs; Day 21, pre-dose, 0.5 hrs; Day 28, pre-dose, 0.5 hrs]
To evaluate the PK of oral doses of MYMD1 capsules
Timeframe: Cohorts 1, 2, 3, 4: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24 hrs; Day 7, pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 24; Day 14, pre-dose, 0.5 hrs; Day 21, pre-dose, 0.5 hrs; Day 28, pre-dose, 0.5 hrs]
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 1 (predose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 1 (0-4 hrs post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 1 (4-8 hrs post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 1(8-24hrs post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 7 (predose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 7 (0-4 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 7 (4-8 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 7 (8-24hrs post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 14 (predose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 14 (0-4 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 14 (4-8 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 14 (8-24 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 21 (predose)
To evaluate the PK of oral doses of MYMD1 capsules
Timeframe: Day 21 (0-4 hrs post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 21 (4-8 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 21 (8-24 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 28 (pre dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 28 (0-4hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 28 (4-8 hours post dose)
To evaluate the PK (urine) of oral doses of MYMD1 capsules
Timeframe: Day 28 (8-24 hours post dose)